Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | F2R | P25116 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179975 | 0.92 | MAPK1 (0.56) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL21349100 | 0.89 | MAPK1 (0.66) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL6212581 | 0.88 | MAPK1 (0.61) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL7475224 | 0.88 | MAPK1 (0.64) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL7565149 | 0.87 | MAPK1 (0.81) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL4129269 | 0.86 | MAPK1 (0.62) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL8796753 | 0.85 | CYP4F2 (0.60) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL28770758 | 0.85 | RAB9A (0.69) | MAPK1LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL17150491 | 0.85 | PDK1 (0.56) | MAPK1LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL8867305 | 0.85 | MAPT (0.61) | MAPK1LMNAMAPTHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709314-A | Efflux pump inhibitor and its therapeutic use | 巴斯利尔药物国际股份公司 | 2018-02-16 | — | — | CN | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20090005364-A1 | Azole Derivatives With Antimuscarinic Activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| EP-1828163-A2 | AZOLE DERIVATIVES WITH ANTIMUSCARINIC ACTIVITY | CHIESI FARMACEUTICI S.p.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066924-A2 | AZOLE DERIVATIVES WITH ANTIMUSCARINIC ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | MAPK1 98/4885LMNA 2650/4885MAPT 4114/4885 |
| US-20090005364-A1 | Azole Derivatives With Antimuscarinic Activity | CHRM2, CHRM3, CHRM1 | MAPK1 1929/4885LMNA 2821/4885MAPT 2824/4885 |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MAPK1 73/4885LMNA 2534/4885MAPT 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.